RecruitingPhase 1Phase 2NCT06548412
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Sponsor
M.D. Anderson Cancer Center
Enrollment
50 participants
Start Date
Jan 22, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate combination therapy of adding CTX-009 to the standard therapy GCD as first-line therapy in patients with unresectable or mBTC.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called CTX-009, a drug called Cisplatin, and others for people with metastatic biliary tract cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGGemcitabine
Given by IV
DRUGCisplatin
Given by IV
DRUGDurvalumab
Given by IV
DRUGCTX-009
Given by IV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06548412